Anti-angiogenesis and anti-tumor effects of AdNT4-anginex

Cancer Letters

Volumn 285, Issue 2, 2009, Pages 218-224

  Dong, Dan Feng ^a   Li, En Xiao ^a   Wang, Ju Bo ^a   Wu, Yin Ying ^a   Shi, Fan ^a   Guo, Jun Jun ^b   Wu, Yuan ^c   Liu, Jun Ping ^d   Liu, Shan Xi ^a   Yang, Guang Xiao ^e  

^a First Affiliated Hospital   (China)

^b Tumor Hospital of Shannxi Province   (China)

^c First Affiliated Hospital   (China)

^d MONASH UNIVERSITY   (Australia)

^e Xi'an Huaguang Biotechnological Co Ltd   (China)

Author keywords

Anginex; Angiogenesis; Anti angiogenesis; Peptide; Recombinant adenovirus

Indexed keywords

ADENOVIRUS VECTOR; ANGINEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CHICK EMBRYO; FEMALE; GENETIC VECTORS; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MUS;

EID: 70349946971     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.05.021     Document Type: Article

References (23)

1. Folkman J., and Klagsbrun M. Angiogenic factors. Science 235 (1987) 442-447
2. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
3. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., and Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
4. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
5. Molema G., and Griffioen A.W. Rocking the foundations of solid tumor growth by attacking the tumor's blood supply. Immunol. Today 19 (1998) 392-394
6. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1 (1995) 27-31
7. Mayo K.H., Haseman J., Ilyina E., and Gray B. Designed β-sheet-forming peptide 33mers with potent human bacterial/permeability increasing protein-like bacterial and endotoxin neutralizing activities. Biochem. Biophys. Acta 1425 (1998) 81-92
8. Mayo K.H., Ilyina E., and Park H. A recipe for designing water-soluble, beta-sheet-forming peptides. Protein Sci. 5 (1996) 1301-1315
9. Gray B.H., Haseman J.R., and Mayo K.H. B/PI-derived synthetic peptides: synergistic effects in tethered bactericidal and endotoxin neutralizing peptides. Biochim. Biophys. Acta 1244 (1995) 185-190
10. Dings R.P., Arroyo M.M., and Lockwood N.A. β-Sheet is the bioactive conformation of the anti-angiogenic anginex peptide. Biochem. J. 373 (2003) 281-288
11. Ilyina E., Roongta V., and Mayo K.H. NMR structure of a de novo designed, peptide 33mer with two distinct, compact β-sheet folds. Biochemistry 36 (1997) 5245-5250
12. Dings R.P., van der Schaft D.W., Hargittai B., Haseman J., Griffioen A.W., and Mayo K.H. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett. 194 (2003) 55-66
13. Griffioen A.W., van der Schaft D.W., Barendsz-Janson A.F., Cox A., Struijker Boudier H.A., Hillen H.F., and Mayo K.H. Anginex, a designed peptide that inhibits angiogenesis. Biochem. J. 354 (2001) 233-242
14. Mayo K.H., van der Schaft D.W., and Griffioen A.W. Designed beta-sheet peptides that inhibit proliferation and induce apoptosis in endothelial cells. Angiogenesis 4 (2001) 45-51
15. van der Schaft D.W., Dings R.P., de Lussanet Q.G., van Eijk L.I., Nap A.W., Beets-Tan R.G., Bouma-TerSteege J.C., Wagstaff J., Mayo K.H., and Griffioen A.W. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J. 16 (2002) 1991-1993
16. Li E.X., Liu S.X., Yang G.X., Wang Q.Y., Wang Q.Y., Wu Y.Y., and Shi F. Construction and identification of the recombinant prokaryotic expression plasmid containingbetapep-25 peptide. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 22 (2006) 154-160
17. Brandwijk R.J.M.G.E., Nesmelova I., Dings R.P.M., Mayo K.H., Thijssen V.L.J.L., and Griffioen A.W. Cloning an artificial gene encoding angiostatic anginex: from designed peptide to functional recombinant protein. Biochem. Biophys. Res. Commun. 4 (2005) 1261-1268
18. Tamura M., Gu J., Matsumoto K., Parsons R., and Yamada Y.M. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280 (1998) 1614-1617
19. Robert A., Rachel L., Brenda S., Louis K., and Nasim A. Angiogenesis assays: a critical overview. Clin. Chem. 49 (2003) 32-40
20. de Lussanet Q.G., Beets-Tan R.G.H., Backes W.H., van der Schaft D.W.J., van Engelshoven J.M.A., Mayo K.H., and Griffioen A.W. Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice. Eur. J. Cancer 40 (2004) 1262-1268
21. Dings R.P., Yokoyama Y., Ramakrishnan S., Griffioen A.W., and Mayo K.H. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res. 63 (2003) 382-385
22. Dings R.P., Williams B.W., Song C.W., Griffioen A.W., Mayo K.H., and Griffin R.J. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cell. Int. J. Cancer 115 (2005) 312-319
23. Mayo K.H., Dings R.P., Flader C., Nesmelova I., Hargittai B., van der Schaft D.W.J., van Eijk L.I., Walek D., Haseman J., Hoye T.R., and Griffioen A.W. Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. J. Biol. Chem. 278 (2003) 45746-45752